Lukas’ memory T cell technology is developed in collaboration with National Cancer Center of Japan. The technology has been validated by Phase III clinical trials in Japan and Korea and used for the treatment of over 10,000 patients in both nations.
Lukas Biomedical is looking for partners wishing to expand immunotherapy technologies in home country or overseas.